Epitope mapping of conformational V2-specific anti-HIV human monoclonal antibodies reveals an immunodominant site in V2. - Wikidata - awgldk - TriplyDB

Epitope mapping of conformational V2-specific anti-HIV human monoclonal antibodies reveals an immunodominant site in V2.

Epitope mapping of conformational V2-specific anti-HIV human monoclonal antibodies reveals an immunodominant site in V2.

http://www.wikidata.org/entity/Q34907398

about

Functional Implications of the Binding Mode of a Human Conformation-Dependent V2 Monoclonal Antibody against HIV The V1V2 Region of HIV-1 gp120 Forms a Five-Stranded Beta Barrel.HIV-1 vaccines: challenges and new perspectives Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge.Nonneutralizing functional antibodies: a new "old" paradigm for HIV vaccines Sequence-conserved and antibody-accessible sites in the V1V2 domain of HIV-1 gp120 envelope protein.Partial rescue of V1V2 mutant infectivity by HIV-1 cell-cell transmission supports the domain's exceptional capacity for sequence variation.Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response.Vaccine-induced Human Antibodies Specific for the Third Variable Region of HIV-1 gp120 Impose Immune Pressure on Infecting Viruses Antibody light-chain-restricted recognition of the site of immune pressure in the RV144 HIV-1 vaccine trial is phylogenetically conserved.Estimated secondary structure propensities within V1/V2 region of HIV gp120 are an important global antibody neutralization sensitivity determinant.Rationally Targeted Mutations at the V1V2 Domain of the HIV-1 Envelope to Augment Virus Neutralization by Anti-V1V2 Monoclonal Antibodies.Identification of New Regions in HIV-1 gp120 Variable 2 and 3 Loops that Bind to α4β7 Integrin Receptor.Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine Research Human Antibodies that Recognize Novel Immunodominant Quaternary Epitopes on the HIV-1 Env Protein.Conserved Role of an N-Linked Glycan on the Surface Antigen of Human Immunodeficiency Virus Type 1 Modulating Virus Sensitivity to Broadly Neutralizing Antibodies against the Receptor and Coreceptor Binding Sites Adenoviral vectors elicit humoral immunity against variable loop 2 of clade C HIV-1 gp120 via "Antigen Capsid-Incorporation" strategy.Rationally Designed Immunogens Targeting HIV-1 gp120 V1V2 Induce Distinct Conformation-Specific Antibody Responses in Rabbits.The HIV-1 gp120 V1V2 loop: structure, function and importance for vaccine development.Monoclonal Antibodies Specific for the V2, V3, CD4-Binding Site, and gp41 of HIV-1 Mediate Phagocytosis in a Dose-Dependent Manner Plasticity and Epitope Exposure of the HIV-1 Envelope Trimer.Distinct mechanisms regulate exposure of neutralizing epitopes in the V2 and V3 loops of HIV-1 envelope.Extracellular Matrix Proteins Mediate HIV-1 gp120 Interactions with α4β7.Particulate Array of Well-Ordered HIV Clade C Env Trimers Elicits Neutralizing Antibodies that Display a Unique V2 Cap Approach.Non-neutralizing Antibodies Targeting the V1V2 Domain of HIV Exhibit Strong Antibody-Dependent Cell-mediated Cytotoxic Activity.Functional Antibody Response Against V1V2 and V3 of HIV gp120 in the VAX003 and VAX004 Vaccine Trials.Reduced cell-associated DNA and improved viral control in macaques following passive transfer of a single anti-V2 monoclonal antibody and repeated SHIV challenges.Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvant.Common helical V1V2 conformations of HIV-1 Envelope expose the α4β7 binding site on intact virions

P2860

Q27681527-91909F08-30CC-4DDF-8E72-429523745A14 Q30152923-6059D4B2-A366-476E-B7DF-5AA85CEC8C23 Q33577972-40543EF8-4FF5-4BB9-ADEF-110BCE44C1DF Q33804531-FC81F560-18CE-4BA0-927E-5AA1162282DF Q34057711-304DD13D-B5FB-44BC-873E-A93C2B972292 Q34116932-6D84E1EB-7473-4185-9EE7-2FCF9AB540EB Q34309493-5DCE91FC-5DDC-4A86-AE04-A3A7D7E85E55 Q34540352-0E5D1A04-A743-448E-8276-30BC3829FCF4 Q34948847-08F1F852-B467-463A-BC3D-AE0645E70170 Q35073270-498435CC-E321-41B1-8F33-675C1AFB8892 Q35140508-471D7689-E538-4089-8819-DD433C5FEB41 Q35817106-33FF824C-28A3-4803-BA6B-70281D00A0AC Q35857404-85825371-C424-4474-B9C1-26CE9E7CF3BB Q35861256-0447E063-E629-45B5-9D15-9A1EE1F63F9A Q36076117-E463728A-813D-49DE-85BE-D6D537988A5D Q36434294-269A66A3-CE21-41BE-B0EB-812D17B073DD Q36625165-136EB053-6A77-4BC7-B3E1-DD58E3A36212 Q37448281-1123BB9B-0DA3-4DBB-ADCD-6D036EF58718 Q38243948-5181592D-A549-4317-B65E-B8838B683F83 Q38719420-37B42D28-5337-414C-A73E-421D195B2181 Q38725480-70EAD4BB-111F-433D-B379-F21D2552741D Q38962226-3C7C59D4-6353-4EE5-8D86-A9DE370048DE Q40080908-29937708-0297-4020-B32F-7896FBC49EF0 Q40198048-611952B8-226F-4B12-AC27-3A9B8498814C Q41924059-D16B1AA9-7D73-403B-B2A1-CDB6EB3B8FA3 Q47555452-A5AD91AD-BBD9-4CE4-87D2-FE77F3B75811 Q51743315-FEE5D068-FDEF-4B16-8283-F815B70F1C9F Q52561260-A6753A9C-C11C-4C69-8B9C-DEB8E0D878D1 Q58115616-8B9EEA4D-C104-4485-8F41-88A77CACF09E

P2860

Epitope mapping of conformational V2-specific anti-HIV human monoclonal antibodies reveals an immunodominant site in V2.

http://www.wikidata.org/entity/Q34907398

description

2013 nî lūn-bûn

@nan

2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Epitope mapping of conformatio ...... an immunodominant site in V2.

@ast

Epitope mapping of conformatio ...... an immunodominant site in V2.

@en

Epitope mapping of conformatio ...... an immunodominant site in V2.

@nl

type

label

Epitope mapping of conformatio ...... an immunodominant site in V2.

@ast

Epitope mapping of conformatio ...... an immunodominant site in V2.

@en

Epitope mapping of conformatio ...... an immunodominant site in V2.

@nl

prefLabel

Epitope mapping of conformatio ...... an immunodominant site in V2.

@ast

Epitope mapping of conformatio ...... an immunodominant site in V2.

@en

Epitope mapping of conformatio ...... an immunodominant site in V2.

@nl

P1433

Q34907398-C112E961-2629-46A1-9D82-68BA3660B5AE

P1476

Q34907398-09F2B0F0-3DF0-4E82-8892-0D48FE8F48B3

P2093

Q34907398-083579E6-BC08-4FD8-89FC-8326BB6CB764

Q34907398-265768F5-A31F-47E3-A12D-7C9FB39EDA94

Q34907398-52AEECA2-9F34-4E86-902D-619A45CB1477

Q34907398-7EA67226-C963-4ED1-A3E8-8DBEE6001711

Q34907398-D38CD51E-EAFE-447C-9865-A9FDCFEF0E04

P2860

Q34907398-0497EB83-6791-4ABA-A674-0311C199D4F8

Q34907398-115E6CF1-2E4F-4BC7-A7B9-977CB3DA9310

Q34907398-134DD6E8-21DB-462D-B640-E674924F4BBC

Q34907398-1C1AC7CA-D835-4E1C-BFB7-9DC79571EE88

Q34907398-3760E62A-E49F-4F3B-A6B0-96B781B54267

Q34907398-39C7525E-F388-47A3-855A-1B64EA1A4874

Q34907398-3CE41A0C-B05A-4F55-BFE6-B9D65EE9C958

Q34907398-4B6611D1-BCA1-40B6-A459-1AF9D0B83765

Q34907398-5047B96E-A8FE-4487-9D9C-A6D321E0C63F

Q34907398-506F8AFD-19F6-4D7C-B432-181EDD12DBBD

P304

Q34907398-8C32C6A0-6512-4B8E-B4CC-D80AF186B756

P31

Q34907398-B4314F5E-D8F2-4610-8946-BDD570332BD5

P356

Q34907398-A2BF69B3-E53E-47C9-9319-68EEE1386C64

P407

Q34907398-95A102BC-A88B-469E-A392-54424F1C6FD3

P433

Q34907398-7CBD0B2C-1ABC-4387-A041-7C3319ED8F4C

P478

Q34907398-A878CAA7-235A-42C4-B47B-F9D530D031A1

P577

Q34907398-6994E38A-67B3-460C-8AD1-EA01E8F9CC10

P5875

Q34907398-A93D280B-90FF-4BB9-9A7D-1973D726B757

P698

Q34907398-6B9CE251-8E56-4B85-A2C5-763122EF31B6

P921

Q34907398-75EAF598-4FA5-4652-B45A-A91297DE58F9

P932

Q34907398-E7A8630B-41B3-4F88-9B13-040515FC74A7

P356

JOURNAL.PONE.0070859

P1433

P1476

Epitope mapping of conformatio ...... an immunodominant site in V2.

@en

P2093

Brett Spurrier

http://www.w3.org/2001/XMLSchema#string

Luzia M Mayr

http://www.w3.org/2001/XMLSchema#string

Sandra Cohen

http://www.w3.org/2001/XMLSchema#string

Susan Zolla-Pazner

http://www.w3.org/2001/XMLSchema#string

Xiang-Peng Kong

http://www.w3.org/2001/XMLSchema#string

P2860

HIV-1 envelope protein binds to and signals through integrin α4β7, the gut mucosal homing receptor for peripheral T cells

Molecular architectures of trimeric SIV and HIV-1 envelope glycoproteins on intact viruses: strain-dependent variation in quaternary structure

Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9

Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2

Functional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individuals

Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

Immune-correlates analysis of an HIV-1 vaccine efficacy trial

Structure prediction for CASP8 with all-atom refinement using Rosetta.

Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals.

P304

e70859

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0070859

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2013-07-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

255696006

http://www.w3.org/2001/XMLSchema#string

P698

23923028

http://www.w3.org/2001/XMLSchema#string

P921

P932

3726596

http://www.w3.org/2001/XMLSchema#string